Compared with GSK2830371 treatment alone, the combination therapy of SB203580 and GSK2830371 led to decreased levels of PARP cleavage, p53 and its downstream apoptotic effector PUMA and Bax after 6 hrs of treatment, indicating that p38 activation by GSK2830371 potentiates p53 activation and its tumor suppressive function in NB cells (Supplementary Fig. S3). This evidence concerns the gene BAX and neuroblastoma.